JPRN-jRCTs041180111已完成3 期
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study
Murohara Toyoaki0 个研究点目标入组 62 人开始时间: 2019年3月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
After 6 months of prednisone treatment for cardiac sarcoidosis, 80.4% of patients had a reduction in the extent of abnormal FDG accumulation, and when the poor-responder group was re-treated with methotrexate or re-prednisone, there was no significant difference in the treatment effect between two groups.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Cardiac sarcoidosis
排除标准
- •1, Bone marrow suppression
- •2, Chronic hepatic disease
- •3, Chronic kidney disease
- •4, Insulin using
- •5, Active infection
- •6, Unsuitable patient
- •7, Under 20 years of age
研究者
相似试验
尚未招募
4 期
Prednisolone for 12 Versus 6 Months to Treat Pulmonary SarcoidosisSarcoidosisNCT06654934Post Graduate Institute of Medical Education and Research, Chandigarh100
Unknown
3 期
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary SarcoidosisPulmonary SarcoidosisNCT05247554Assistance Publique - Hôpitaux de Paris200
已完成
不适用
Factor influencing successful treatment outcome of repeated corticosteroid injection for trigger finger: Prospective cohort studyPatients were a diagnosis of trigger finger disease, a history of corticosteroid injections in the treated fingerTrigger fingerCorticosteroid injectionTCTR20230221004Chulalongkorn University114
招募中
3 期
Cardiac Sarcoidosis Randomized TrialCardiac SarcoidosisSarcoidosisNCT03593759Ottawa Heart Institute Research Corporation160
终止
不适用
Treatment of Renal Sarcoidosis by Methylprednisolone BolusRenal SarcoidosisNCT01652417Assistance Publique - Hôpitaux de Paris40